Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (IMR) Price & Analysis

Compare

7 Followers

IMR Stock Chart & Stats

AU$1.64

Market closed

AU$1.64

Day’s Range― - ―

52-Week RangeAU$1.12 - AU$2.25

Previous CloseN/A

VolumeN/A

Average Volume (3M)287.54K

Market Cap

AU$641.89M

Enterprise ValueAU$358.06M

Total Cash (Recent Filing)AU$40.81M

Total Debt (Recent Filing)AU$26.62M

Price to Earnings (P/E)―

Beta2.14

Next Earnings

Sep 01, 2026

EPS Estimate

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.00

Shares Outstanding320,947,020

10 Day Avg. Volume240,875

30 Day Avg. Volume287,535

Financial Highlights & Ratios

PEG Ratio0.36

Price to Book (P/B)27.34

Price to Sales (P/S)1042.05

P/FCF Ratio-15.61

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

AU$2.61

Price Target Upside58.94% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)-0.06

Revenue Forecast (FY)AU$3.48M

Bulls Say, Bears Say

Bulls Say

Recurring Consumable RevenueImricor’s consumable-led revenue model creates recurring per-procedure revenue if clinical adoption grows. Consumables tied to each procedure can provide predictable, repeatable cash flow over time and improve margin leverage once procedure volumes scale.

Specialized MR-conditional Product NicheThe company’s focus on MR-conditional EP catheters targets a distinct clinical niche with technical barriers to entry. This specialization can create durable differentiation versus standard EP tools, supporting premium positioning as MRI-guided ablation adoption expands.

Balance Sheet Equity ImprovementRestoring positive equity materially reduces short-term insolvency risk and improves access to capital markets or strategic partners. A positive equity base strengthens credibility with lenders and suppliers, aiding medium-term financing and commercialization plans.

Bears Say

Collapsing And Volatile RevenueA deep, persistent revenue decline signals weak commercial traction and limited market penetration of core products. Without sustained revenue growth, the company cannot achieve economies of scale, making long-term margin improvement and operational leverage unlikely.

Sustained Cash Burn And Negative FCFConsistent, large negative operating and free cash flows necessitate external funding to sustain operations. Ongoing cash burn increases dilution or refinancing risk, constraining long-term strategy execution and potentially forcing cutbacks in R&D or commercialization investments.

Elevated Leverage And Refinancing RiskHigh debt relative to equity raises interest and covenant risk, limiting financial flexibility. If losses persist, the company faces refinancing or repayment pressure that could lead to onerous terms, higher costs, or shareholder dilution when raising new capital.

Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh News

Imricor outlines FY 2025 investor presentation under strict disclosure and compliance caveats

Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( ($AU:IMR) ) has issued an announcement....

13d ago

IMR

Imricor Marks Pivotal Year as MRI-Guided Cardiac Platform Gains Regulatory and Commercial Traction

Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( ($AU:IMR) ) just unveiled an update....

13d ago

IMR

Imricor Widens Adjusted Loss as It Ramps Up Spending Ahead of U.S. and European Growth Push

Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( ($AU:IMR) ) has shared an announcement....

13d ago

IMR

Imricor Seeks FDA 510(k) Clearance for Advantage-MR MRI-Guided EP System

An announcement from Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( ($AU:IMR) ) is...

1M ago

IMR

Imricor Adds Oklahoma Heart Institute as Fourth U.S. Site in VISABL-AFL Trial

Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( ($AU:IMR) ) has issued an announcement....

1M ago

IMR

Imricor Wins Landmark FDA Clearance for MRI-Native NorthStar Mapping System

Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( ($AU:IMR) ) has shared an announcement....

1M ago

IMR

Imricor Advances MRI-Guided Cardiac Ablation Platform Amid Clinical Milestones and Cash Burn

Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( ($AU:IMR) ) has issued an update....

1M ago

IMR

Imricor Adds Virginia Commonwealth University as Third U.S. Site in VISABL-AFL Trial

Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( ($AU:IMR) ) has issued an update....

2M ago

IMR

Imricor Options Lapse, Slightly Simplifying Capital Structure

An announcement from Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( ($AU:IMR) ) is...

2M ago

IMR

Imricor Issues 155,000 Unquoted Options Under Employee Incentive Plan

Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( ($AU:IMR) ) has issued an announcement....

2M ago

IMR

IMR FAQ

What was Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s price range in the past 12 months?

Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh lowest share price was AU$1.11 and its highest was AU$2.25 in the past 12 months.

What is Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s market cap?

Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s market cap is AU$641.89M.

When is Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s upcoming earnings report date?

Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s upcoming earnings report date is Sep 01, 2026 which is in 176 days.

How were Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s earnings last quarter?

Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh released its earnings results on Feb 24, 2026. The company reported AU$0 earnings per share for the quarter, beating the consensus estimate of -AU$0.032 by AU$0.032.

Is Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh overvalued?

According to Wall Street analysts Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh pay dividends?

Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh does not currently pay dividends.

What is Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s EPS estimate?

Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s EPS estimate is 0.

How many shares outstanding does Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh have?

Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh has 320,947,020 shares outstanding.

What happened to Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s price movement after its last earnings report?

Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh reported an EPS of AU$0 in its last earnings report, beating expectations of -AU$0.032. Following the earnings report the stock price went up 1.508%.

Which hedge fund is a major shareholder of Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh?

Currently, no hedge funds are holding shares in AU:IMR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Stock Smart Score

Underperform

Fundamentals

Return on Equity

-432.03%

Trailing 12-Months

Asset Growth

634.84%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh

Imricor Medical Systems, Inc., a medical device company, designs, manufactures, sells, and distributes magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures in the United States. The company's principal products include the Advantage-MR EP Recorder/Stimulator system, an EP recording system and integrated cardiac stimulator; Vision-MR Ablation Catheter, which is used as an indication for treating type I atrial flutter; and Vision-MR Dispersive Electrode that is used to minimize eddy currents induced on the conductive pads during MR scanning. It also performs contract research, as well as licenses its intellectual property for use in implantable devices. Imricor Medical Systems, Inc. was incorporated in 2006 and is headquartered in Burnsville, Minnesota.

Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (IMR) Earnings & Revenues

Historic Earnings Reports

IMR Stock 12 Month Forecast

Average Price Target

AU$2.61

▲(58.94% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"AU$0","3":"AU$3","0.75":"AU$0.75","1.5":"AU$1.5","2.25":"AU$2.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2.78,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$2.78</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.6066666666666665,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$2.61</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$2.33</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,0.75,1.5,2.25,3],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.95,2.0138461538461536,2.0776923076923075,2.1415384615384614,2.2053846153846153,2.269230769230769,2.333076923076923,2.396923076923077,2.4607692307692304,2.5246153846153847,2.588461538461538,2.652307692307692,2.716153846153846,{"y":2.78,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.95,2.0005128205128204,2.051025641025641,2.1015384615384614,2.152051282051282,2.2025641025641023,2.253076923076923,2.303589743589743,2.354102564102564,2.4046153846153846,2.455128205128205,2.5056410256410255,2.5561538461538458,{"y":2.6066666666666665,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.95,1.9792307692307691,2.0084615384615385,2.0376923076923075,2.066923076923077,2.0961538461538463,2.125384615384615,2.1546153846153846,2.183846153846154,2.213076923076923,2.2423076923076923,2.2715384615384617,2.3007692307692307,{"y":2.33,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.36,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.44,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.579,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.425,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.425,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.69,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.55,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.22,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 41, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.425,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.53,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.95,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >